Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.72 |
| ▸ | HTR2B | P41595 | 9/20 | 0.72 |
| ▸ | HTR2A | P28223 | 5/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914900 | 1.00 | HTR2C (0.72) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5417225 | 0.90 | HTR2C (0.73) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5421871 | 0.89 | HTR2C (0.75) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5408380 | 0.89 | HTR2C (0.72) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5418598 | 0.88 | HTR2C (0.70) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5419945 | 0.87 | HTR2C (0.77) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5847626 | 0.87 | HTR2C (0.77) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5413099 | 0.87 | HTR2C (0.95) | HTR2CHTR2BHTR2A | |
| SCHEMBL5416869 | 0.87 | HTR2C (0.69) | HTR2CHTR2BHTR2ASIGMAR1 | |
| SCHEMBL5407367 | 0.86 | HTR2C (0.79) | HTR2CHTR2BHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209864-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | HTR2C 2/4885HTR2B 8/4885HTR2A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.